Liver Injury After Shingrix: Beyond Case Reports
Based on the available FDA drug label and postmarketing surveillance data, liver injury (DILI) from Shingrix is NOT documented in the official safety profile, suggesting it remains limited to isolated case reports if reported at all.
Evidence from Official Sources
The FDA drug label for Shingrix 1 does not list hepatotoxicity or liver injury among its postmarketing adverse reactions. The documented postmarketing adverse events include:
- Decreased mobility of the injected arm
- Hypersensitivity reactions (angioedema, rash, urticaria)
- Guillain-Barré syndrome (with observational study data showing 3 excess cases per million doses)
Large-Scale Postmarketing Surveillance Findings
Multiple comprehensive pharmacovigilance studies analyzing tens of thousands of adverse event reports found no signals for liver injury:
VAERS analysis of 66,849 reports (2017-2024) identified predominantly reactogenic events—pyrexia, injection site reactions, chills, headache—with no mention of hepatic adverse events 2
Analysis of 69,822 VAERS reports showed injection-site and influenza-like reactions as the primary safety signals, with serious reports comprising only 6.6% of cases (2.9% for Shingrix specifically). Liver injury was not identified as a disproportionate signal 3
Real-world pharmacovigilance study (May 2006-December 2024) found RZV-associated adverse events primarily manifested as transient reactogenicity, with no hepatic signals detected 4
Active surveillance of 647,833 RZV doses using electronic health records monitored 10 prespecified outcomes and detected no sustained increased risk for any monitored outcome, with no mention of hepatic events 5
Clinical Interpretation
The absence of liver injury from:
- FDA-approved drug labeling
- Multiple large-scale postmarketing surveillance systems
- Active electronic health record monitoring
- Disproportionality analyses across hundreds of thousands of doses
This strongly suggests that if liver injury occurs with Shingrix, it remains at the level of isolated case reports and has not reached the threshold for regulatory recognition or signal detection in pharmacovigilance systems.
Important Caveats
- The provided evidence focuses on commonly reported adverse events (injection site reactions, GBS, herpes zoster reactivation)
- Rare idiosyncratic reactions may not be captured in voluntary reporting systems
- The question specifically asks about case reports, which by definition represent rare, individual occurrences not yet established as causally related
In clinical practice, if a patient develops liver injury temporally associated with Shingrix vaccination, this should be reported to VAERS, but clinicians should maintain a high index of suspicion for alternative etiologies given the lack of established association in large-scale surveillance.